NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in combination with donepezil HCl tablets, in patients with Alzheimer’s disease.1,2 Based on the Phase 1 study results, PF-04360365 has advanced into Phase 2.3 Dimebon (latrepirdine), being co-developed by Pfizer and Medivation Inc., is in Phase 3 development.4 These data were presented this week at the Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD) in Vienna, Austria.
